Notice of Correction to RFA-CA-20-047 “Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)"
Notice Number:
NOT-CA-21-004

Key Dates

Release Date:

October 9, 2020

Related Announcements

RFA-CA-20-047 - Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to clarify and/or replace requirements for levels of effort to RFA-CA-20-047 - Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required).

The following sections of the FOA are revised:

Section IV. Application and Submission Information

Part 2. Content and Form of Application Submission, Budget (Administrative Core)

Currently reads:

The U19 overall PD/PI(s) is/are expected to serve as Core Lead of the Administrative Core with a minimum effort of 0.6 person months. If multiple PD/PIs serve as co-leads of the Administrative Core, each is expected to devote at least 0.6 person months. The minimum total effort for each PD/PI or MPI of the U19 is 2.4 person months in aggregate for all functions served on the U19.

Revised to (in italics):

At least one of the U19 overall PD/PI(s) is expected to serve as Core Lead of the Administrative Core with a minimum effort of 0.6 person months. If multiple PD/PIs serve as co-leads of the Administrative Core, each is expected to devote at least 0.6 person months. The minimum total effort for each PD/PI or MPI of the U19 is 2.4 person months in aggregate for all functions served on the U19.

Part 2. Content and Form of Application Submission, Budget (Research Project)

Currently reads:

Each Research Project must be led by a minimum of two co-leaders: one laboratory scientist and one clinical researcher. Each Project Leader should devote at least 1.8 person months effort (15%).

Revised to (in italics):

Each Research Project must be led by a minimum of two co-leaders: one laboratory scientist and one clinical researcher. Each co-leader is expected to devote effort of at least 0.9 person months per Research Project.

All other aspects of RFA-CA-20-047 are unchanged.

Inquiries

Please direct all inquiries to:

Suzanne Forry, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5922
Email:forryscs@mail.nih.gov

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: wolfreyc@mail.nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices